MEDICLINIC INTERNATIONAL PLC - Tax treatment of ordinary share dividend for shareholders on the South African register

Release Date: 12/12/2018 14:00
Code(s): MEI
 
Wrap Text
Tax treatment of ordinary share dividend for shareholders on the South African register

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9950122714
("Mediclinic", the "Company" or the "Group")

12 December 2018

TAX TREATMENT OF ORDINARY SHARE DIVIDEND FOR SHAREHOLDERS ON THE
SOUTH AFRICAN REGISTER

Background

Shareholders on the South African register of the Company are referred to Mediclinic's
announcement of the results for the six months ended 30 September 2018 and dividend
declaration released on the Stock Exchange News Service and on the Regulatory News Service
on 15 November 2018, confirming that the Board of Directors of Mediclinic had declared an
interim dividend from retained earnings of 3.20 pence per ordinary share for the six months
ended 30 September 2018.

The interim dividend will be paid on Tuesday, 18 December 2018 to all ordinary shareholders
who are on the register of members at the close of business on the record date of Friday, 7
December 2018.

Shareholders on the South African register will be paid the ZAR cash equivalent of 59.16800
cents (47.33440 cents net of dividend withholding tax) per share. A dividend withholding tax of
20% will be applicable to all shareholders on the South African register who are not exempt
therefrom. The ZAR cash equivalent has been calculated using the following exchange rate:
GBP1: ZAR18.49, being the 5-day average ZAR/GBP exchange rate (Bloomberg) on Friday, 9
November 2018 at 3:00pm GMT.

Tax treatment for shareholders on the South African register

South African tax resident shareholders on the South African register:

In terms of the Company's Dividend Access Trust structure, eligible South African tax resident
shareholders on the South African register set out below will receive the full dividend, namely
59.16800 cents per share, from the Dividend Access Trust and therefore regarded as a local
South African dividend. For purposes of South African dividend withholding tax, the entire
dividend of 59.16800 cents per share is taxable at a rate of 20%, unless an applicable
exemption applies:

1.    in the case of shares held in certificated form, eligible shareholders who are registered
      on the South African register with an address in South Africa (other than PLC Nominees
      Proprietary Limited (or any successor entity through which shares held in dematerialised
      form are held)); and

2.    in the case of shares held in dematerialised form, in respect of whom the South African
      transfer secretaries of the Company have determined, in good faith and by reference to
      the information provided to them by the eligible shareholders and/or their brokers and/or
      central securities depository participants, that such eligible shareholders are either (i) tax
      resident in South Africa or (ii) have an address in South Africa and have not expressly
      indicated that they are not tax resident in South Africa as at the dividend record date.

Non-South African tax resident shareholders on the South African register:

Non-South African tax resident shareholders on the South African register will be paid the
dividend by the Company in the usual way and not through the Dividend Access Trust. The
entire dividend of 59.16800 cents per share payable to such shareholders will therefore be
regarded as a foreign dividend and exempt from South African dividend withholding tax,
provided that the relevant exemption forms have been completed and submitted as prescribed.

About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in
Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core
purpose is to enhance the quality of life of patients by providing acute care, specialist-
orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire
Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 76 hospitals and 30 clinics. Hirslanden operates 18 private hospitals and
4 clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates
48 hospitals and 4 day clinics throughout South Africa and 3 hospitals in Namibia with more
than 8 100 inpatient beds in total; and Mediclinic Middle East operates 7 hospitals and 22 clinics
with more than 900 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with
secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 12/12/2018 02:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story